LARC-EX: Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells

Sponsor
Oslo University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT02113384
Collaborator
The Research Council of Norway (Other)
231
1
184
1.3

Study Details

Study Description

Brief Summary

During the course of tumor growth and possibly by manipulation during the surgical procedure, cells from rectal tumors may be shed into the peritoneal cavity. Such cells may give rise to local recurrence or contribute to the formation of metastatic disease, specifically in the form of peritoneal carcinomatosis. Detection of cancer cells in the peritoneal cavity at the time of surgery might therefore be of value for prediction of disease recurrence with subsequent prognostic implications for these patients. In this study the investigators aim to determine the presence of exfoliated tumor cells in peritoneal lavage samples from patients undergoing surgery for LARC.

Condition or Disease Intervention/Treatment Phase
  • Other: Observational study.

Detailed Description

The investigators recently published a study investigating the incidence of exfoliated cancer cells in peritoneal lavage fluid after resection of locally advanced rectal cancer (LARC). DNA isolated from cells obtained by peritoneal lavage was analyzed by denaturing capillary electrophoresis with respect to mutations in hotspots of the K-RAS gene. This gene is mutated in 30% of rectal tumors. Exfoliated tumor cells (as assessed by the presence of mutated DNA) were found in lavage fluid from 19/237 of the patients, and the presence of tumor cells was associated with poor overall survival. Based on these encouraging results the investigators have designed a more comprehensive prospective study, using a novel, validated set of cancer specific DNA methylation - based biomarkers present in the vast majority of all colorectal tumors (sensitivity 94%, specificity 98%).Using these tumor cell associated biomarkers, the investigators aim to determine the presence of exfoliated tumor cells in peritoneal lavage samples from patients undergoing surgery for LARC. Lavage will be performed prior to and after manipulation of the tumor to provide data regarding both spontaneous and iatrogenic tumor cell exfoliation and their respective contribution to patient outcome. If detection of exfoliated tumor cells is predictive of tumor recurrence, this would support an active approach to postoperative chemotherapy, possibly in the form of intraperitoneal chemotherapy.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
231 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Prospective Observational Study of Exfoliated Peritoneal Tumor Cells in Locally Advanced Rectal Cancer
Actual Study Start Date :
Sep 1, 2012
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Jan 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Observational study

Patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.

Other: Observational study.
Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
Other Names:
  • Observational study. Laboratory biomarker analysis.
  • Outcome Measures

    Primary Outcome Measures

    1. Overall survival [5 years]

      Time from surgery until death from any cause

    Secondary Outcome Measures

    1. Disease-free survival [5 years]

      Time from surgery until disease recurrence or death

    2. Disease-free survival [3 years]

      Time from surgery until disease recurrence or death

    3. Overall survival [3 years]

      Time from surgery until death from any cause

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients scheduled for surgical removal of a primary locally advanced rectal tumor at the Norwegian Radium Hospital.

    • age > 18 years

    • written informed consent

    Exclusion criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Norwegain Radium Hospital Oslo Ullern Norway 0310

    Sponsors and Collaborators

    • Oslo University Hospital
    • The Research Council of Norway

    Investigators

    • Study Chair: Bjørn-Atle Bjørnbeth, MD PhD, Oslo University Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kjersti Flatmark, Professor, Oslo University Hospital
    ClinicalTrials.gov Identifier:
    NCT02113384
    Other Study ID Numbers:
    • Larc-Ex_09/2012
    First Posted:
    Apr 14, 2014
    Last Update Posted:
    Jul 28, 2021
    Last Verified:
    Jul 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Keywords provided by Kjersti Flatmark, Professor, Oslo University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 28, 2021